# US 2016/0256512 A1 · Method for the management of cancer and cancer treatment-related comorbidities

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256512 A1
- Document ID: US20160256512A1
- Status: Published application
- Kind: A1
- Application number: 15/032,179
- Filed: 2014-11-07
- Published: 2016-09-08
- Earliest claimed: 2013-11-08
- Assignees: Legacy Healthcare Ltd.
- Applicants: Legacy Healthcare Ltd
- Inventors: Saad HARTI; JiaWei LIU
- Web page: https://patentgrep.com/patent/US20160256512A1

## CPC

- A61K 36/88: Liliopsida (monocotyledons)
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 36/5777: {Theobroma, e.g. cocao or cocoa}
- A61K 36/752: Citrus, e.g. lime, orange or lemon
- A61K 36/77: Sapindaceae (Soapberry family), e.g. lychee or soapberry
- A61K 36/8962: Allium, e.g. garden onion, leek, garlic or chives
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 7/06: Antianaemics
- A61P 17/00: Drugs for dermatological disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/24: Antidepressants
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for the management of cancer and treatment of cancer comorbidities, including but not limited to cancer-related fatigue, cachexia, anorexia, pain, anemia, asthenia, depression, muscle weakness, nausea, vomiting, skin, and skin appendages adverse reactions; the method including the administration by the conventional and non-conventional oral, topical, parenteral routes and intra-tumoral injection, or in combination thereof, or the administration as adjuvant potentiator in other therapies using the forenamed routes, of a composition containing as active ingredient an extract of Allium species, which contains querceting, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.

## Claims

### Claim 1

A method for management of cancer and for treatment of cancer comorbidities, including but not limited to cancer-related fatigue, cachexia, anorexia, pain, anemia, asthenia, depression, muscle weakness, nausea, vomiting, skin, and skin appendages adverse reactions; the method comprising administering by both conventional and non-conventional routes, and/or as adjuvant potentiator in cell therapies, or topical route, or parenteral route, or intra-tumoral injection, or in combination thereof, a composition comprising as an active ingredient an extract of Allium species, which comprises quercetin, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species.

### Claim 2 (depends on 1)

A method for the management of the cancer and for the treatment of the cancer comorbidities according to claim 1, wherein the composition contains an extract of the Allium species, which contains quercetin, an extract of the Citrus species, an extract (atomized or not) of the Paullinia species and an extract (atomized or not) of the Theobroma species.

### Claim 3 (depends on 1)

A method for the management of the cancer and for the treatment of the cancer comorbidities, according to claim 1, wherein the composition comprises: from 30% to 93% by weight of the extract of the Allium species, quercetin, from 3% to 33% by weight of the extract of the Citrus species, from 0.10% to 2.5% by weight of the extract (atomized or not) of the Paullinia species, and from 0.10% to 2.5% by weight of the extract (atomized or not) of the Theobroma species, based on the total weight of the four active ingredients.
